Lilly submits complete responses on both KwikPen applications

Eli Lilly filed amendments on December 2, 2025 that the Food and Drug Administration accepted as complete responses to action letters the agency had issued on January 29, 2025, for the tirzepatide KwikPen applications covering both Mounjaro and Zepbound ^[1][2]. The FDA approved both supplements about seven weeks later, on January 20, 2026 ^[1][2].

The approvals apply to two separate applications. NDA 217806/S-002 covers Zepbound KwikPen, and the original supplement was submitted November 15, 2023 ^[1]. NDA 215866/S-009 covers Mounjaro KwikPen, with an original submission date of September 28, 2023 ^[2]. Both were Prior Approval supplements, meaning FDA sign-off was required before Lilly could market the changes ^[1][2].

Each approval adds six new KwikPen presentations, and each new pen contains four doses of tirzepatide in a fixed volume for once-weekly injection, according to the approval letters ^[1][2]. The letters do not specify which dose strengths are included in the six presentations, since that volume information was redacted in the public documents ^[1][2]. The approvals also came with revised Prescribing Information, Medication Guides, and new carton, container labeling, and Instructions for Use for the KwikPen ^[1][2]. Both letters direct Lilly to make a small labeling tweak, changing "mg/dose" to "mg per dose" for clarity ^[1][2].

FDA determined that neither supplement triggered pediatric study requirements under the Pediatric Research Equity Act, because the changes did not involve a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration ^[1][2]. The agency's Office of Cardiology, Hematology, Endocrinology, and Nephrology, under Deputy Director Lisa B. Yanoff, signed off on both letters ^[1][2].

Why it matters for patients

More KwikPen presentations could mean more dose options or pack sizes become available for people using Mounjaro or Zepbound, though the sources do not spell out which specific doses or volumes the six new presentations represent ^[1][2]. Both letters describe manufacturing and labeling changes rather than any change to how the drug works or who it is prescribed for ^[1][2].

The nearly year-long gap between FDA's original action letters in January 2025 and Lilly's December 2025 response suggests the company needed substantial time to address whatever manufacturing or chemistry issues the agency had flagged ^[1][2]. The sources do not explain what specifically the FDA's January 2025 action letters required Lilly to fix, only that the December 2, 2025 amendments were accepted as complete responses ^[1][2].

For patients already on tirzepatide, the practical effect may show up gradually as pharmacies and distributors update stock to reflect new KwikPen packaging and Instructions for Use ^[1][2]. Both approval letters note that Lilly must submit final printed carton and container labeling within 30 days of it becoming available, and update structured product labeling within 14 days of the approval date, so consumer-facing packaging changes may follow in stages rather than all at once ^[1][2].

What happens next

Lilly has 14 days from the January 20, 2026 approval date to submit updated content of labeling in structured product labeling format ^[1][2]. The company also has 30 days after printing to submit final printed carton and container labeling for both the Zepbound and Mounjaro KwikPen supplements ^[1][2]. Separately, patent information tied to each approved supplement is due to FDA within 30 days of the approval date for listing in the Orange Book ^[1][2]. The sources do not indicate when the six new KwikPen presentations will actually reach pharmacies.